A detailed history of Ensign Peak Advisors, Inc transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 2,435,426 shares of XFOR stock, worth $2.34 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,435,426
Holding current value
$2.34 Million
% of portfolio
0.01%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$0.72 - $1.46 $1.75 Million - $3.56 Million
2,435,426 New
2,435,426 $3.39 Million
Q2 2022

Aug 12, 2022

SELL
$0.88 - $1.91 $155,346 - $337,172
-176,530 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$1.9 - $5.6 $281,080 - $828,447
147,937 Added 517.39%
176,530 $404,000
Q1 2021

May 12, 2021

SELL
$6.63 - $10.28 $9,739 - $15,101
-1,469 Reduced 4.89%
28,593 $246,000
Q4 2020

Feb 12, 2021

SELL
$5.41 - $7.4 $54,668 - $74,777
-10,105 Reduced 25.16%
30,062 $193,000
Q3 2020

Nov 12, 2020

BUY
$6.09 - $9.15 $207,291 - $311,447
34,038 Added 555.36%
40,167 $272,000
Q1 2020

May 11, 2020

SELL
$6.03 - $11.01 $36,957 - $67,480
-6,129 Reduced 50.0%
6,129 $61,000
Q4 2019

Feb 14, 2020

BUY
$9.93 - $14.33 $121,721 - $175,657
12,258 New
12,258 $131,000

Others Institutions Holding XFOR

About X4 Pharmaceuticals, Inc


  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $65.9M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.